Siemens Healthineers CEO on Antibody Test, Rebalancing Business

The transcript discusses the production and impact of a coronavirus antibody test, including regulatory clearance and production capacity. It covers pricing strategies, market competition, and the company's focus on helping society. The impact of the pandemic on business operations, including the withdrawal of guidance and the effect on non-elective surgeries, is also addressed. Additionally, the transcript explores opportunities in medical production related to coronavirus, such as blood clots and cardiovascular treatment.

What is the expected production capacity for the coronavirus antibody test by June?

• 10 million tests

• 100 million tests

• 25 million tests

• 50 million tests

What is the primary focus of the company regarding the pricing of the antibody test?

• Maximizing profit

• Offering discounts

• Helping in the critical situation

• Regional competition

Why did the company withdraw its business guidance for the year?

• To focus on new product development

• Due to increased competition

• Due to a change in leadership

• Because of the pandemic's impact on non-elective surgeries

What is the expected impact on the diagnostics business due to the reduction in elective procedures?

• Significant increase

• Significant decrease

• Minor increase

• No change

What is the company's approach to the delay in hospital equipment installations?

• Wait for the pandemic to end

• Cancel all orders

• Expect pent-up demand and maintain a solid order book

• Shift focus to other products

What is the company's strategic advantage in fighting diseases like coronavirus?

• Strong position in hemostasis and cardiovascular treatment

• Partnerships with legislators

• Focus on in vivo imaging only

• Exclusive production of masks

What new opportunities are being explored by the company in relation to coronavirus?

• Entering the mask production market

• Developing new imaging technologies

• Exploring cardiovascular treatment advancements

• Focusing solely on antibody tests